10-Q: Vaxart Reports Second Quarter 2024 Financial Results and Provides Business Update

Vaxart's second quarter 2024 results show increased revenue from government contracts and a net loss, alongside progress in clinical trials and strategic funding agreements.

Summary

• Vaxart reported a net loss of $16.47 million for the three months ended June 30, 2024, and $40.88 million for the six months ended June 30, 2024.
• The company's revenue increased significantly due to government contracts, reaching $6.4 million for the quarter and $8.6 million for the six-month period.
• Research and development expenses were $17.48 million for the quarter and $36.49 million for the six-month period.
• Vaxart's cash, cash equivalents, and investments totaled $62.6 million as of June 30, 2024.
• The company expects its current cash runway to extend into 2026.
• Vaxart entered into an agreement with Advanced Technology International for up to $452.9 million to conduct a Phase 2b study of its oral COVID-19 vaccine candidate.
• The company also received a $9.3 million contract from HHS BARDA to support clinical trial planning activities.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in terms of funding and clinical trial progress, the company's financial losses and dependence on future capital raises temper the overall sentiment. The risk of delisting from Nasdaq also adds a negative element.

Positives

• Vaxart secured significant funding through government contracts, including up to $452.9 million for a Phase 2b COVID-19 vaccine study.
• The company's cash position improved to $62.6 million, providing a runway into 2026.
• Vaxart is advancing its oral vaccine platform with ongoing clinical trials for COVID-19 and norovirus.
• The company has a strong focus on developing mucosal vaccines, which may offer advantages over traditional injectable vaccines.

Negatives

• Vaxart reported a net loss of $16.47 million for the three months ended June 30, 2024, and $40.88 million for the six months ended June 30, 2024.
• The company is still dependent on raising additional capital to continue operations.
• Research and development expenses remain high, totaling $17.48 million for the quarter and $36.49 million for the six-month period.

Risks

• Vaxart is dependent on raising additional capital through the sale of securities, borrowings, or partnerships.
• The company's ability to continue as a going concern is dependent on securing additional funding.
• There is no assurance that Vaxart will be successful in raising additional capital.
• The company's stock is currently trading below the Nasdaq minimum bid price requirement, which could lead to delisting.
• HHS BARDA has the right to terminate the 2024 ASPR-BARDA Contract and the 2024 ATI-RRPV Contract for convenience, which could significantly impact Vaxart's revenue and cash flow.
• The company is subject to ongoing litigation, which could result in substantial costs and a diversion of management's attention.

Future Outlook

Vaxart expects to continue advancing its oral vaccine candidates through clinical trials and regulatory approvals, while also exploring strategic partnerships and additional funding opportunities. The company anticipates initiating the Phase 2b clinical trial for its COVID-19 vaccine candidate in the second half of 2024.

Management Comments

• Based on management's current plan, the Company expects to have cash runway into 2026.
• The Company will be dependent upon raising additional capital through placement of its common stock, notes or other securities, borrowings, or entering into a partnership with a strategic party in order to implement its business plan.

Industry Context

The announcement reflects the ongoing efforts in the biotechnology industry to develop novel vaccine technologies, particularly oral vaccines, which offer potential advantages in terms of ease of administration and broader immune responses. The focus on COVID-19 and norovirus aligns with current public health priorities.

Comparison to Industry Standards

• Vaxart's approach to oral vaccine development is unique compared to many competitors who focus on injectable vaccines, such as Moderna and Pfizer.
• The company's reliance on government funding through contracts like the ASPR-BARDA and ATI-RRPV agreements is similar to other biotech companies working on pandemic preparedness.
• The reported net losses are typical for clinical-stage biotech companies that are heavily investing in research and development.
• The company's cash runway into 2026 is a positive sign, but it will need to continue to raise capital to support its operations and clinical trials.

Legal Proceedings

• The company is involved in ongoing legal proceedings, including securities class actions and a lawsuit related to short-swing profits.
• A partial settlement was reached in the securities class action, with the company agreeing to pay $2 million.
• A motion for summary judgment was granted in the short-swing profits lawsuit, but the plaintiff has filed an appeal.

Stakeholder Impact

• Shareholders face the risk of stock dilution due to potential capital raises and the risk of delisting from Nasdaq.
• Employees may be affected by potential cost-cutting measures if the company fails to secure additional funding.
• Customers (potential patients) may benefit from the development of new oral vaccines.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Vaxart expects to initiate the Phase 2b clinical trial for its COVID-19 vaccine candidate in the second half of 2024.
• The company will continue to pursue regulatory approvals for its vaccine candidates.
• Vaxart will continue to explore strategic partnerships and additional funding opportunities.

Key Dates

Keywords

COVID-19 vaccine, oral vaccine, clinical trial, government contracts, HHS BARDA, Phase 2b study, mucosal vaccine, biotechnology, VAAST platform, norovirus vaccine